Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
David P. Ryan(East Carolina University), Joseph P. Eder(Yale Cancer Center), Mayer Fishman(Moffitt Cancer Center), Leonard J. Appleman(University of Pittsburgh), James C. Cusack(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Jeffrey G. Supko(Harvard University), Peter C. Enzinger(Dana-Farber Cancer Institute), Oscar Kashala(Millennium Engineering and Integration (United States)), P. Fidias(Asklepios Fachkliniken München-Gauting), Thomas J. Lynch(Nationwide Children's Hospital)
Cited by 49
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k